IL33 and asthma: Currently, clinical trials are assessing the efficacy of anti-IL-33 monoclonal antibody treatments (Itepekimab, Etokimab and Tozorakimab) in chronic obstructive pulmonary disease, asthma, atopic dermatitis and peanut allergy [127–130].